Recent experimental animal studies have shown that fetal exposure to serotonin reuptake inhibitors (SRIs) affects brain development. Modern recording methods and advanced computational analyses of scalp electroencephalography (EEG) have opened a possibility to study if comparable changes are also observed in the human neonatal brain. We recruited mothers using SRI during pregnancy (n = 22) and controls (n = 62). Mood and anxiety of mothers, newborn neurology, and newborn cortical function (EEG) were assessed. The EEG parameters were compared between newborns exposed to drugs versus controls, followed by comparisons of newborn EEG features with maternal psychiatric assessments. Neurological assessment showed subtle abnormalities in the SRI-exposed newborns. The computational EEG analyses disclosed a reduced interhemispheric connectivity, lower cross-frequency integration, as well as reduced frontal activity at low-frequency oscillations. These effects were not related to maternal depression or anxiety. Our results suggest that antenatal serotonergic treatment might change newborn brain function in a manner compatible with the recent experimental studies. The present EEG findings suggest links at the level of neuronal activity between human studies and animal experiments. These links will also enable bidirectional translation in future studies on the neuronal mechanisms and long-term neurodevelopmental effects of early SRI exposure.
Introduction
Serotonin reuptake inhibitors (SRIs) are used in the treatment of major depressive disorder (MDD), anxiety disorders, and eating disorders, all of which commonly require medical care during pregnancy (Andrade et al. 2008; Hanley and Mintzes 2014) . The rate of use of SRIs during pregnancy has rapidly increased to even 5-8% of pregnant women (Charlton et al. 2015; Dawson et al. 2015) . The SRI exposure has not been associated with salient teratogenic effects (Reefhuis et al. 2015; Wemakor et al. 2015) , and there is a concern that untreated antenatal depression may adversely impact the early development of the offspring (Gentile 2015; Hanley et al. 2015) . The current guidelines hence support the pharmacological treatment of severe maternal symptoms to reduce their impact on the mother and offspring (Ray and Stowe 2014; Gentile 2015) . Recent clinical findings have, however, challenged the view that SRIs do not affect early brain development (Hermansen and Melinder 2015; Man et al. 2015) .
In this context, it is relevant to consider the rapidly accumulating data from experimental neuroscience. The serotonergic systems, including the SRI target serotonin transporter, are now known to serve crucial ontogenetic roles during fetal brain development (Nordquist and Oreland 2010; Bourke et al. 2013) . These effects include, for instance, guidance of neuronal migration and growth of neuronal networks (Borue et al. 2007; Homberg et al. 2010; Kiryanova et al. 2013 ). An experimental SRI exposure in utero is shown to distort cortical and subcortical microstructures and function (Persico et al. 2001; Xu et al. 2004; Liao and Lee 2011; Simpson et al. 2011; Suri et al. 2015) . However, recent scientific debate on the early use of brainacting drugs has exposed the many challenges that arise when attempting direct translation of cellular-level experimental findings to the pharmacological treatment of human infants (Durrmeyer et al. 2010) . It has become apparent that the translational bridges from experimental findings to human infants should be more specific, and preferably be based on translational comparisons at the level of specific biological mechanisms.
While the molecular and histological effects of SRI exposure are not accessible in live human newborns, brain function could readily be studied in the human infants as well. Animal studies have reported clear effects of fetal SRI exposure on early neurophysiological functions (Liao and Lee 2011; Simpson et al. 2011; Zhou et al. 2015) , such as a reduced functional network connectivity related to disorganized cortical histology (Simpson et al. 2011) . Recent rapid advancement in the recording and analysis techniques of newborn scalp electroencephalography (EEG) has opened novel possibilities to directly assess functional cortical connectivity, both between and within brain regions (Vanhatalo et al. 2005; Tokariev et al. 2012 Tokariev et al. , 2015 Räsänen et al. 2013) . The cellular-level mechanisms of these computational EEG features are now understood (Engel et al. 2013; Hyafil et al. 2015; Sotero et al. 2015) . Importantly, the recent basic science data suggest that some detailed features, such as interplay between cortical layers and the developmentally transient subplate circuitry, could be studied by measuring specific cross-frequency interactions in the neonatal EEG (Minlebaev et al. 2007; Colonnese et al. 2010) . Hence, the recent signal analytic advance has opened a potential translational bridge between experimental animal work and human EEG recordings even at the level of neuronal network mechanisms.
Taken together, it is now well established (Borue et al. 2007; Homberg et al. 2010 ) that the use of SRI during pregnancy may affect molecular and histological development of the fetal brain, which are also reflected in the early neuronal network functions. It is as yet unknown, however, whether such effects could also be seen in the human after in utero SRI exposure. We hypothesized that novel measures of newborn electrical brain activity could offer a translational bridge needed to benchmark human newborns with experimental studies at the mechanistic level. To test this overall hypotheses, we set 3 aims: (1) to investigate whether prenatal SRI exposure affects the newborn electrical activity to a measurable degree, (2) to compare early and later neonatal EEG changes in order to distinguish EEG signs of neonatal abstinence from longer-lasting developmental effects, and (3) to assess whether these possible effects are related to the level of maternal depression or anxiety. To achieve these aims, we designed computational EEG analyses that reflect different neuronal mechanisms recently implicated in the preclinical experiments on early SRI exposure.
Materials and Methods

Participants
Mothers were recruited from the Health Care Centers in Espoo, Finland, during routine prenatal follow-up, or via advertising in newspapers and public places. The inclusion criteria were: ongoing pregnancy and SRI medication. Exclusion criteria were: maternal antidepressive medication other than SRIs, use of antipsychotics or mood-stabilizing medication, diagnosis of bipolar disorder, and substance abuse disorder. Infants born preterm were excluded. A control cohort of 62 pregnant women with no SRI was recruited via the same media and with the same exclusion criteria. Recruitment lasted from January 2012 to June 2014. The study was conducted within the area of Helsinki University Hospital and was approved by the local ethics committee. An informed consent was obtained from all mothers. All clinical and neurophysiological studies, including EEG assessment, were carried out blindly without knowing the exposure status of the newborn.
Clinical Studies
Psychiatric Assessments of the Mother
We assessed perinatal baseline status in all women with SRI medication (n = 22) and most (61%) of controls during the last week (average 0.2 days; ±13.3 days) before delivery. A psychiatrist (H.S. and O.M.) interviewed the mother and completed the Research Version of The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) interview. A consensus between the 2 psychiatrists on diagnosis was done after all interviews. Both parents completed a self-questionnaire which contained information on socio-demographic characteristics, smoking, alcohol use during pregnancy, and medications. The medication was also assessed in the interview. The severity of current symptoms of depression (Beck Depression Inventory, BDI; Beck et al. 1961) , anxiety (Beck Anxiety Inventory, BAI; Beck et al. 1988) , and harmful alcohol use (Alcohol Use Disorders Identification Test; Babor et al. 2001) were evaluated using well-validated symptom scores.
Neurological Examination of the Newborn
Newborn neurological status was examined by a pediatric neurologist (M.V.) at the average postnatal age of 1.3 weeks (Table 1) . This timing was considered to be beyond the period of acute abstinence syndrome (Kieviet et al. 2013; Forsberg et al. 2014) , hence allowing a search for longer-lasting symptoms and their association with the neurophysiological findings. Two welldocumented, structured assessments were used: Hammersmith Neonatal Neurological Examination scale (HNNE; Dubowitz et al. 1999) and Modified Finnegan Neonatal Abstinence Scoring System (Finnegan and Kaltenback 1992) . We calculated the 6 categories of HNNE Scores and the Total Score according to Dubowitz et al. (1999) . The HNNE categories (Tone, Tone patterns, Reflexes, Movements, Abnormal signs, and Orientation and behavior) correspond to different attributes of newborn neurology.
Neurophysiological Studies of the Newborns
EEG Recordings
We performed 2 EEG recordings in each newborn: the first within a week after birth (Rec 1) and the second at about 2 weeks postnatally (Rec 2). This allowed distinguishing the EEG reactions related to the acute withdrawal of fetal SRI (Rec 1) from longerlasting EEG effects (Rec 2). The EEG signals were collected as previously described (Videman et al. 2016 ) using NicOne EEG amplifier (Cardinal Healthcare/Natus, USA) and EEG caps with at least 20 electrodes (sintered Ag/AgCl electrodes; Waveguard, ANT-Neuro, Germany). The following polygraphic channels were included for sleep state assessment according to standard criteria (Andre et al. 2010) : chin electromyogram, electrocardiogram, eye movements, and respiratory sensors. No hardware filters were applied to avoid distortion of EEG signals during data collection. All EEG recordings were visually reviewed to exclude clinically meaningful abnormalities, and we extracted epochs of relatively artifact-free EEG signal during active sleep and quiet sleep [QS; for more detailed description, see Supplementary Material and Videman et al. (2016) ]. These epochs were converted to the standard European Data Format for further computational analyses.
EEG Analysis
All computational analyses were quantitative and performed using custom-made Matlab codes. See Supplementary material for further technical details of the analysis pipeline (see Supplementary Fig. 1 ). Most of the Matlab scripts used in our present work are available in our previously published work (Videman et al. 2016) .
To evaluate the local cortical function, we examined 3 measures: First, the ability to generate and sustain local oscillatory transients was quantified by measuring the frontal alpha bouts (FA; Fig. 1A ), a characteristic feature of neonatal EEG (Andre et al. 2010; Videman et al. 2016) . Second, the local integration between oscillatory frequencies was assessed by measuring phaseamplitude coupling with nestedness coefficient (NC, Fig. 1B ), which is a robust measure to characterize cross-frequency interaction during spontaneous activity transients in the neonatal EEG (Vanhatalo et al. 2005; Tokariev et al. 2015) , and considered to arise from a coordination of spatially overlapping but functionally distinct neuronal networks (Engel et al. 2013; Hyafil et al. 2015; Sotero et al. 2015) . Third, we also measured the frequency spectra at each electrode location to provide a benchmark for the conventional spectral analyses.
To evaluate cortical function at a more global level, we examined 4 measures that reflect different physiological mechanisms of brain network function: First, interhemispheric integration, or interhemispheric synchrony, was assessed with activation synchrony index (ASI, Fig. 1C ; Räsänen et al. 2013) , which is shown to be a robust sign of normally developing neonatal long-range cortico-cortical connectivity (Koolen et al. 2014 ). Second, global intermittency, which is conventionally considered to be a sign of newborn EEG maturity (Biagioni et al. 2007) , was estimated from objectively quantified interburst intervals (IBIs, Fig. 1C ) during trace alternant, the characteristic EEG activity during QS periods. Third, spectral analyses of individual electrodes were pooled together to obtain global frequency-specific assessment of oscillatory brain activity. Fourth, we supplemented our analysis by performing comprehensive computation of hemispheric asymmetries across the whole frequency spectra. This was done to benchmark our data with the recent literature that has suggested a differential asymmetry in the anterior alpha activity in the offspring of depressive mothers (Thibodeau et al. 2006; Field and Diego 2008; Diego et al. 2010; Goldstein and Klein 2014; Lusby et al. 2014) .
Statistical Analysis
As the data were often not normally distributed (BDI, BAI, and NCs), we performed all group comparisons using nonparametric statistics: Fisher's exact test, Wilcoxon signed-rank test (within individual), Wilcoxon rank-sum test (between individuals), or Spearman's correlation coefficient. Analyses with multiple comparisons were controlled as described in detail before (Tokariev et al. 2015) .
Results
Clinical Characterization of the Mothers
Psychiatric Assessments
The psychiatric evaluations, background information on smoking, alcohol consumption, and educational level of the parents are summarized in Table 2 . Mothers using SRI had more often a current anxiety disorder (but not MDD), as well as a lifetime diagnosis of MDD or anxiety disorder; these differences were also reflected in the symptom scores at the time of delivery. Breastfeeding was equally common in both groups (80%) at the time of the EEG recordings and the clinical examinations. Information about breastfeeding was not reliably available from about one-sixth of the mothers (5 of SRI mothers and 9 of control mothers).
SRI Medication
The prevalences of medications and average daily dosages used were sertraline 6 (47.5 mg), escitalopram 6 (8 mg), citalopram 6 (17.5 mg), paroxetine 2 (30 mg), venlafaxine 2 (75 mg), duloxetine 1 (60 mg), and mirtazapine 1 (15 mg). Four mothers reported SRI polytherapy. Of 22 mothers with medication, 16 had medication throughout pregnancy, 21 had the medication in the first and second trimester, 1 finished and 1 started it in the end of the second trimester, and 4 finished it during the last 2-4 weeks before delivery.
Newborn Clinical Findings
There were no significant differences in the perinatal clinical information between newborn groups, with only a marginal, clinically unremarkable difference in the cord pH (Table 1) . There was one outlier in 1-min Apgar (Apgar = 2) in the control group, but though we excluded this outlier, the mean score for Apgar did not differ significantly (controls: mean 8.6, range 5-10, SD ±1.07 and SRI: 8.7, 6-10, ±0.81, P = 0.64). We could not observe signs of abstinence syndrome at the mean postnatal age of 9 days using the Finnegan score (Table 3) , which suggests that the acute SRI withdrawal effects had tapered by that time. However, neurological examination at the same time showed significant differences between the groups, especially in the HNNE category of "Abnormal signs or patterns," which includes aspects of tremor, hand and toe posture, and startle reaction ( Table 3 ). The subscore analysis showed that the newborns exposed to SRI had also more tremors during wakefulness (P = 0.05).
Neurophysiological Studies
Local Brain Function
In the first EEG recordings, there was a significant difference between newborn groups in the local ability to sustain periodic oscillatory bouts. The mean length of frontal alpha bouts was shorter in the SRI than in the control group (0.34 s, SD 0.06 vs. 0.44 s, SD 0.10, P = 0.005). This group difference was only transient during the perinatal period (Rec 1), and it had disappeared by the second EEG recording (Rec 2). The measure of local cross-frequency integration (NC) was different between newborn groups at the second EEG recording time. The newborns exposed to SRI showed lower mean levels of NC when compared with the control newborns. The direction of difference between group means was consistent over the whole range of frequencies (Fig. 2) , but due to interindividual variability, the group difference in frequency-specific analyses reached formal statistical significance only at 5.7 Hz (0.17, SD 0.06 vs. 0.19, SD 0.06, P = 0.034), which is within the dominant frequency band of bursting network activity in the term neonatal EEG [for more details, see Tokariev et al. (2012) ].
Global Brain Function
The measure of interhemispheric connectivity (ASI) showed lower levels of global integration in the newborns exposed to SRI. A comparable difference in ASI levels was found both during the first (4.26, SD 2.27 vs. 6.42, SD 1.80, P = 0.006) and the second EEG recording (3.91, SD 1.71 vs. 6.01, SD 1.24, P < 0.001, Fig. 3 ). Notably, the ASI levels remained relatively constant within the groups from the first to the second EEG recording, suggesting a developmental persistence of interhemispheric synchrony. The global average of spectral amplitudes showed significant differences between the control and SRI group at all lower frequencies (0.7-2.0 Hz; Fig. 4A) . A further spatial analysis using electrodelevel group comparisons showed that the significant difference is concentrated to frontal brain regions. The global intermittency of activity measured with median occipital IBIs was shorter in the SRI group during the second recording (4.71 s, SD 0.61 vs. 5.07 s, SD 0.57, P = 0.037).
Comparison of hemispheric asymmetries at specific frequency bands showed no global-level group difference between SRI and control newborns at any frequency. An electrode-level comparison, however, disclosed a group difference between SRI and control newborns at the alpha and beta frequencies of both frontal and temporal brain regions (Fig. 4B) .
Newborn Brain Function Versus Maternal Psychiatric Assessments
Maternal mood is known to affect different aspects of early neurobehavioral development (Gentile 2015) . Hence, in a post hoc analysis, we wished to assess 2 alternative explanations for the found differences in the EEG measures between SRI and control infants. First, could the newborn EEG findings be explained by an unknown, inherited "endophenotype" (Goldstein and Klein 2014) seen as an EEG difference according to mothers' lifetime history of depression or anxiety? Second, could the newborn EEG findings be related to mood-or anxiety-related factors like hormones during pregnancy, reflected as a correlation with mother's BAI or BDI scores? Dubowitz et al. (1999) , mean (range, SD). In the analysis with cases and controls pooled together, our EEG parameters suggested very few and seemingly erratic albeit formally statistically significant relations to maternal mood or anxiety. To provide a comprehensive overview, Supplementary Material shows comparisons of maternal psychiatric measures to all EEG features that we found to have statistically significant SRI effects (see above). Overall, based on the analysis of statistical significance, as well as the effect direction and size in the total sample, we conclude that the main findings are more likely explained by medication exposure or an interaction with medication and mood/anxiety rather than by lifetime or current depression or anxiety. Furthermore, neither the EEG parameters nor the clinical findings differed significantly in respect of maternal educational level (see Supplementary Table 1) .
Discussion
This is the first study to show that prenatal SRI exposure in humans can affect the newborn cortical function beyond the acute withdrawal period. Our detailed quantitative, computational EEG analyses indicated SRI-related effects in both focal and global brain activity. Some effects were only seen during the first postnatal week, and they might be reflections of the acute adaptation after postnatal SRI abstinence. However, lower interhemispheric connectivity (ASI), lower local cross-frequency integration (NC), and changes in the QS (IBI) outlasted the acute withdrawal time period, suggesting more long-lasting developmental effects by prenatal SRI exposure. Moreover, comparison of EEG with maternal symptoms suggested that these changes are likely due to medication or an interaction with medication and mood/anxiety rather than maternal depression or anxiety per se. While comparable, advanced EEG analyses have not been performed in prior human studies, our findings are fully compatible with recent experimental work that has suggested a range of neurodevelopmental effects by early SRI exposure.
Translational Comparisons
Previous preclinical studies have suggested multiple mechanisms through which a prenatal SRI exposure may affect brain development of the offspring. The early developmental changes in the expression of serotonin transporter (5-HTT) gene are known to be region-specific, with particular differences between frontal versus deeper brain expressions, and they converge toward more mature patterns soon after birth (Homberg et al. 2010; Kiryanova et al. 2013 ). These 5-HTT expressions are genetically scheduled; however, they are also affected by various hormonal factors that may be involved in the epigenetic effects, such as maternal psychiatric status or fetal drug exposure (Oberlander et al. 2009; Homberg et al. 2010; Kiryanova et al. 2013) .
Our computational EEG measures were designed to target mechanisms that allow bridging from the human scalp EEG to experimental animal studies. Prior preclinical work in rodent models showed that early SRI exposure exerts widespread histological changes in the brain networks (Xu et al. 2004; Simpson et al. 2011) . Most importantly in the present context, the work by Simpson et al. (2011) reported significant reduction in the callosal nerve fibers, as well as a reduction in cortico-cortical synchronization of neuronal activity. These are fully compatible with our present finding that interhemispheric, that is, presumably callosally mediated, synchrony is reduced in human infants after in utero SRI exposure. The other histological and electrophysiological abnormalities in the cortical networks of SRI-exposed experimental models (Xu et al. 2004; Homberg et al. 2010; Liao and Lee 2011) may readily offer a cellular-level basis for our other observations. For instance, we found reduction in cross-frequency integration that relies on an effective interplay in the local cortical-subcortical (including subplate) networks (Hyafil et al. 2015) . We also found a significant reduction of lowfrequency EEG activity in the frontal areas, which is the last of cortical regions to mature (Andre et al. 2010) . Prior rodent work has reported a transient frontal expression of serotonin transporters and a reduced arborization of prefrontal dendritic branching after SRI exposure during the first postnatal week (Homberg et al. 2010) , which roughly equals to the last trimester of human gestation (Clancy et al. 2007 ). These findings from rodent models support the idea that the observed frontal EEG effects may be particularly due to last trimester SRI exposure.
Withdrawal Versus Sustained
A clinically well-known consequence of fetal SRI exposure is the acute perinatal abstinence syndrome including neurological symptoms such as jitteriness, irritability, and lower habituation (Oberlander et al. 2009; Forsberg et al. 2014; Ray and Stowe 2014) . The peak incidence of the abstinence symptoms occurs 2-90 h postnatally (Ter Horst et al. 2008; Warburton et al. 2010; Salisbury et al. 2011; Forsberg et al. 2014; Ray and Stowe 2014) . Our results are in line with the recent study of Salisbury et al. (2016) that shows neurological effects of SRI exposure can substantially outlast the immediate withdrawal syndrome. Here we observed that many EEG effects are clearly visible at the second recording, on average over 2 weeks after birth, which suggests that the SRI effects on EEG would more likely reflect effects on brain development rather than direct drug effects on brain activity. This interpretation is compatible with the now clinically wellestablished idea that early developmental compromises, such as prematurity-related respiratory distress, circulatory compromise, or fetal drug exposures, would manifest themselves at term age as long-lasting effects in EEG maturation (Hahn and Tharp 1990; Nunes et al. 2014; Videman et al. 2016) .
Pharmacological Versus Maternal Effects
The few prior clinical studies have suggested that maternal depression and/or anxiety may not only affect the later neurobehavioral development of the offspring (Thibodeau et al. 2006; Field and Diego 2008) , but there may even be an association to the newborn EEG activity (Biagioni et al. 2007; Thibodeau et al. 2008) . When examining relationships and frequencies between newborn EEG and maternal psychiatric symptoms in our study cohort, the findings were not consistent with a presence of a neonatal EEG "endophenotype" of maternal depression (Goldstein and Klein 2014). A closer comparison of our methods with those used in earlier studies suggests that an obvious analytical confounder cannot be excluded as the source of reported neonatal EEG "endophenotypes": First, the prior studies have not distinguished between vigilance states (44,45), which we showed recently to have major effects on all EEG metrics (Tokariev et al. 2015) . Pooling EEG epochs from different sleep states will strongly bias the EEG measures, so that they reflect the infant's sleep stage rather than a genuine brain phenotype. Notably, our extensive practical experience shows that sleeping behavior per se is affected by maternal symptoms. Second, prior studies have used generally less EEG data, and they included more variable amount of EEG into the analysis, which are practically reasoned by a lack of good quality data. However, such compromises will necessarily affect group-level findings, especially because the availability of EEG data is inherently biased by covariance with the infant's restlessness (see also above). In partial accordance with the earlier studies, our more stringent recording and signal analysis did result in observing an EEG asymmetry with greater left-side amplitudes. This asymmetry, however, was related to maternal drug treatment rather than maternal psychiatric status. We also extend prior reports by showing this EEG effect at a wider frequency range as well as in wider brain areas, which were not examined in the earlier works due to their recording constraints (44,45).
Methodological Considerations
There were some methodological details that should be considered when comparing our work with the previous literature. Our study was prospective, and the status of mothers was evaluated using stringent psychiatric evaluation including current and lifetime mood and anxiety, while newborns underwent a blinded EEG analysis and structured neurological examinations. This made our study considerably labor-intensive when compared with many previous studies using retrospective or registry-based data collection (Forsberg et al. 2014; Malm et al. 2015; Wemakor et al. 2015 ).
Our patient recruitment was based on SRI use instead of the need for psychiatric intervention for MDD, hence our sample includes individuals with no or mild symptoms of depression. Indeed, practically none of our mothers were currently having any other psychiatric treatment, and the most common indication of chronic SRI treatment in our cohort was prevention of previous severe anxiety disorder (Table 2) . Such a population with mixed SRI indications and a more variable psychiatric status is unlike in most previous studies; however, it allowed us to distinguish analytically the effects of maternal drug treatment and psychiatric symptoms. Another key advantage in our study design was the early examination of SRI effects, which is the only way to limit, if not fully eliminate, the impact of a significant confounder, the postnatal environment, including mother-child interactions. It is neurobiologically plausible to conclude that the reported EEG effects are more likely due to in utero effects than the postnatal environment. Future studies should aim at sampling cohorts that enable analysis of specific drug molecules and timing of exposure.
Though the basic mechanisms of action are analogous between various SRIs, the effects and placental transfer rates of SRIs may vary as shown in earlier studies (Noorlander et al. 2008; Amodeo et al. 2015) . The fact that we had 7 different SRIs in our study could be one possible confounding factor. Though the metabolism of SRIs in the neonatal period is not fully understood (Gentile 2005; Ter Horst et al. 2008) , the elimination halftimes below 40 h (the only exception being sertraline up to 4 days) suggest that the blood levels of SRIs of placental origin were minimal if any by the time of our second EEG recording (mean age 17 days), as well as the neurological examination (mean age 10 days). However, since plasma levels of SRI medications at the time of EEG recordings were not available, we cannot fully exclude the possibility of babies receiving SRIs via breastfeeding. We also could not statistically exclude the effect of maternal smoking because of the small number of smokers among mothers (Table 2 ). These factors are very unlikely to explain our present findings; however, more studies with larger sample sizes and different populations will be needed to define the potential of these maternal factors to affect the observed EEG metrics.
We report statistical correlations and group differences; hence, this work does not provide direct evidence needed for a genuine causal reasoning. The main output of our present work is the identification of human EEG correlates of SRI exposure, which opens 2 directions of future research: First, larger-scale follow-up studies in humans will be able to search for the clinical significance of the observed EEG changes with respect to later neurodevelopment (Hermansen and Melinder 2015; Man et al. 2015) . Second, the observed EEG changes allow benchmarking with future preclinical studies where animal models are used to learn about the cellular-and molecular-level mechanisms, as well as to test the already promising intervention strategies (Zhou et al. 2015) . Finally, our present findings may provide further evidence for a critical attitude toward the use of SRIs during pregnancy (Hanley et al. 2015) and stress the importance of finding non-medical treatments for depressive and anxiety symptoms. An ultimate implication of this is recognition of the need to re-evaluate treatment guidelines for depression and anxiety in nonsymptomatic mothers.
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